Format

Send to

Choose Destination
Annu Rev Med. 2019 Jan 27;70:183-196. doi: 10.1146/annurev-med-041217-011106.

Postpartum Depression: Pathophysiology, Treatment, and Emerging Therapeutics.

Stewart DE1,2,3,4, Vigod SN1,5.

Author information

1
Department of Psychiatry, University of Toronto, Toronto, Ontario M5G 2C4, Canada; email: donna.stewart@uhn.ca.
2
Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ontario M5G 2C4, Canada.
3
Toronto General Hospital Research Institute, Toronto, Ontario M5G 2C4, Canada.
4
University Health Network Centre for Mental Health, Toronto, Ontario M5G 2C4, Canada.
5
Women's College Research Institute, Women's College Hospital, Toronto, Ontario M5G 2C4, Canada; email: simone.vigod@wchospital.ca.

Abstract

Postpartum depression (PPD) is common, disabling, and treatable. The strongest risk factor is a history of mood or anxiety disorder, especially having active symptoms during pregnancy. As PPD is one of the most common complications of childbirth, it is vital to identify best treatments for optimal maternal, infant, and family outcomes. New understanding of PPD pathophysiology and emerging therapeutics offer the potential for new ways to add to current medications, somatic treatments, and evidence-based psychotherapy. The benefits and potential harms of treatment, including during breastfeeding, are presented.

KEYWORDS:

allopregnanolone; emerging therapies; genetic aspects; pathophysiology; postpartum depression

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center